Target Name: UBAC1
NCBI ID: G10422
Other Name(s): Kip1 ubiquitination-promoting complex protein 2 | Glialblastoma cell differentiation-related protein 1 | UBADC1 | Putative glialblastoma cell differentiation-related protein | kip1 ubiquitination-promoting complex protein 2 | UBAC1_HUMAN | Kip1 ubiquitination-promoting complex subunit 2 | GBDR1 | putative glialblastoma cell differentiation-related protein | testicular secretory protein Li 64 | UBA domain-containing protein 1 | RP11-432J22.3 | Ubiquitin-associated domain-containing protein 1 | UBA domain containing 1 | Ubiquitin associated domain containing 1 | E3 ubiquitin-protein ligase subunit KPC2 | ubiquitin associated domain containing 1 | glialblastoma cell differentiation-related protein 1 | KPC2

Unveiling the Potential of UBAC1: A Drug Target and Biomarker for Ubiquitin-Proteasome Complex (UPC) Disruptions

Introduction

The ubiquitin-proteasome (UPC) complex is a crucial molecular machine that regulates protein degradation in cells. Disruptions in the UPC can lead to a range of cellular defects, including misfolded proteins, protein-protein interactions gone awry, and increased protein stability. UBAC1 protein, also known as Kip1 ubiquitination-promoting complex protein 2, is a key player in the regulation of UPC function. In this article, we will explore the potential of UBAC1 as a drug target and biomarker for UPC disruptions.

The UPC: A Complex Machine of Protein Degradation

The UPC is a highly conserved protein complex that plays a central role in regulating protein degradation in eukaryotic cells. It consists of a core protein, Kip1, and several peripheral proteins that form a framework for the recruitment of ubiquitin and other proteins for protein degradation. The UPC uses a hierarchical mechanism to recruit ubiquitin-proteasome (UPN) components to specific target proteins for degradation. UPNs are composed of a core protein and several peripheral proteins that form a ring-like structure around the UPN core. The UPN core can interact with the target protein to recruit it for degradation via the ubiquitin-proteasome interaction. Once recruited, the target protein is ubiquitinated and then processed by the UPN to remove the ubiquitin and release the protein for degradation.

UBAC1: A Key Player in the UPC

UBAC1, also known as Kip1 ubiquitination-promoting complex protein 2, is a 21-kDa protein that is highly conserved in both human and mouse cells. It is a key component of the UPC and plays a critical role in regulating the degradation of target proteins . UBAC1 is composed of a N-terminal region, a transmembrane region, and a C-terminal region. The N-terminal region contains a nucleotide-binding oligomerization domain (NBO), which is responsible for the interaction with UPNs. The transmembrane region contains a putative transmembrane domain and a carboxy-terminal region that is involved in the formation of the UPC. The C-terminal region contains a calcineurin-like domain, which is involved in the regulation of protein stability.

UBAC1's Role in UPC Function

UBAC1 is involved in multiple aspects of UPC function. First, it is the protein that forms the nucleotide-binding oligomerization domain (NBO) and interacts with UPNs to recruit them to the UPC. The NBO domain is responsible for the interaction with UPNs and is critical for the formation of the UPN. Second, UBAC1 is involved in the regulation of UPC stability. The calcineurin-like domain is involved in the regulation of protein stability and has been shown to play a role in the regulation of UPC stability. Finally, UBAC1 is involved in the degradation of target proteins. Once recruited to the UPC, UBAC1 is involved in the ubiquitination and degradation of target proteins.

The Potential of UBAC1 as a Drug Target

The discovery of UBAC1 as a potential drug target is an exciting development in the field of ubiquitin-proteasome (UPC) research. UBAC1 is a key player in the regulation of UPC function, and targeting it may be a promising strategy for the development of new UPC disruptions therapies. Several approaches have been proposed to target UBAC1, including small molecule inhibitors, monoclonal antibodies, and protein-based assays.

small molecule inhibitors:

Small molecule inhibitors have been shown to be effective in

Protein Name: UBA Domain Containing 1

Functions: Non-catalytic subunit of the KPC complex that acts as E3 ubiquitin-protein ligase. Required for poly-ubiquitination and proteasome-mediated degradation of CDKN1B during G1 phase of the cell cycle

More Common Targets

UBAC2 | UBAC2-AS1 | UBALD1 | UBALD2 | UBAP1 | UBAP1L | UBAP2 | UBAP2L | UBASH3A | UBASH3B | UBB | UBBP1 | UBBP2 | UBBP4 | UBC | UBD | UBDP1 | UBE2A | UBE2B | UBE2C | UBE2CP3 | UBE2CP4 | UBE2D1 | UBE2D2 | UBE2D3 | UBE2D3P1 | UBE2D4 | UBE2DNL | UBE2E1 | UBE2E2 | UBE2E3 | UBE2F | UBE2F-SCLY | UBE2FP1 | UBE2G1 | UBE2G2 | UBE2H | UBE2HP1 | UBE2I | UBE2J1 | UBE2J2 | UBE2K | UBE2L1 | UBE2L3 | UBE2L6 | UBE2M | UBE2MP1 | UBE2N | UBE2NL | UBE2O | UBE2Q1 | UBE2Q2 | UBE2Q2P1 | UBE2Q2P11 | UBE2Q2P13 | UBE2Q2P16 | UBE2Q2P2 | UBE2QL1 | UBE2R2 | UBE2R2-AS1 | UBE2S | UBE2T | UBE2U | UBE2V1 | UBE2V1P2 | UBE2V1P9 | UBE2V2 | UBE2V2P1 | UBE2W | UBE2Z | UBE3A | UBE3B | UBE3C | UBE3D | UBE4A | UBE4B | UBFD1 | UBIAD1 | Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 | Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex | UBL3 | UBL4A | UBL4B | UBL5 | UBL5P3 | UBL7 | UBL7-DT | UBLCP1 | UBN1 | UBN2 | UBOX5 | UBOX5-AS1 | UBP1 | UBQLN1 | UBQLN1-AS1 | UBQLN2 | UBQLN3 | UBQLN4 | UBQLNL | UBR1